Worth reading
53Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
8.1
% (year-on-year change in revenue)Wording
Conditional
How definitive the wording is.Results for this period
Full year1 July 2024 to 30 June 2025ConsolidatedJapanese GAAPNet Sales1,455¥ millionYear on year +8.1%Progress 90.9%
Operating profit249¥ millionYear on year +13.3%Progress 83.0%
Ordinary income240¥ millionYear on year -0.2%Progress 80.0%
Net income attributable to owners of the parent256¥ millionYear on year +5.4%Progress 98.5%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share43.67円
Operating Margin17.1％
Financial position at period-end
Total assets2,374¥ million
of which net assets 1,908 ¥ millionEquity ratio 79.6%vs. prior year-end +6.9pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+373
Investment-197
Financials-369
Net change-193
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥1,594 million
Segment revenueAdvanced research and development support business ¥1,143,006 thousand (YoY -3.7%), Healthcare solutions business ¥311,998 thousand (YoY +96.4%)
Segment profitAdvanced research and development support business ¥184,585 thousand (YoY -40.6%), Healthcare solutions business ¥64,935 thousand
Regional sales¥1,304,099 thousand, ¥31,670 thousand, ¥119,234 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥1,600 million (YoY +10.0%)
Operating profit¥300 million (YoY +20.2%)
Ordinary income¥300 million (YoY +24.5%)
Net income¥260 million (YoY +1.4%)
Annual Dividend Forecast¥15 → ¥18（+20.0%）
Payout ratio39.4
Factors Behind Changes in Business Performance
高感度網羅解析サービスの受注拡大、アカデミア・食品分野での大型案件の獲得、機能性素材開発支援サービスの新規受注獲得により売上が増加した。提携サービスの仕入原価、設備増強に伴う減価償却費、賃上げによる人件費、貸倒引当金が増加し、為替差損9,368千円を計上した。
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Yesそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 / Excluded 0 / Company name None
Material subsequent eventsNo applicable matters.
Impairment loss¥0 thousand
Breakdown of extraordinary income (loss)Extraordinary income Gain on reversal of subscription rights to shares ¥35,757 thousand / Extraordinary loss Impairment Loss on Investment Securities ¥7,000 thousand
Depreciation and amortization¥103,812 thousand
Orders received and order backlogOrders received ¥1,450,783 thousand / Order backlog ¥573,862 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (institutional investors and analysts)
Issued Shares at Period-End5,919,797
Treasury Shares at Period-End227,644
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 July 2024 to 30 June 2025 |
| Net Sales | ¥1,455 million (YoY +8.1%) |
| Operating profit | ¥249 million (YoY +13.3%) |
| Ordinary income | ¥240 million (YoY -0.2%) |
| Profit attributable to owners of the parent | ¥256 million (YoY +5.4%) |
| Net income per share | 43.67円 |
| Operating Margin | 17.1％ |
| Equity ratio | End of the current fiscal period 79.6 / End of previous period 72.7 |
| Total assets | ¥2,374 million |
| Net assets | ¥1,908 million |
| Cash flows from operating activities | ¥373 million |
| Cash flows from investing activities | ¥-197 million |
| Cash flows from financing activities | ¥-369 million |
| Cash and cash equivalents at end of period | ¥1,594 million |
| Full-year earnings forecast | Net Sales ¥1,600 million (YoY +10.0%) / Operating profit ¥300 million (YoY +20.2%) / Ordinary income ¥300 million (YoY +24.5%) / Net income ¥260 million (YoY +1.4%) |
| Annual Dividend Forecast | ¥15 → ¥18（+20.0%） |
| Payout ratio | 39.4 |
| Segment revenue | Advanced research and development support business ¥1,143,006 thousand (YoY -3.7%), Healthcare solutions business ¥311,998 thousand (YoY +96.4%) |
| Segment profit | Advanced research and development support business ¥184,585 thousand (YoY -40.6%), Healthcare solutions business ¥64,935 thousand |
| Regional sales | ¥1,304,099 thousand, ¥31,670 thousand, ¥119,234 thousand |
| Orders received and order backlog | Orders received ¥1,450,783 thousand / Order backlog ¥573,862 thousand |
| Depreciation and amortization | ¥103,812 thousand |
| Impairment loss | ¥0 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on reversal of subscription rights to shares ¥35,757 thousand / Extraordinary loss Impairment Loss on Investment Securities ¥7,000 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (institutional investors and analysts) |
| Issued Shares at Period-End | 5,919,797 |
| Treasury Shares at Period-End | 227,644 |
| Factors Behind Changes in Business Performance | 高感度網羅解析サービスの受注拡大、アカデミア・食品分野での大型案件の獲得、機能性素材開発支援サービスの新規受注獲得により売上が増加した。提携サービスの仕入原価、設備増強に伴う減価償却費、賃上げによる人件費、貸倒引当金が増加し、為替差損9,368千円を計上した。 |
Items this document does not state (2)
Revision to Earnings ForecastShareholder Return Policy
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.国内の高感度網羅解析サービスやアカデミア・食品分野で大型案件を獲得し、ヘルスケア・ソリューション事業でも新規受注を拡大した。一方、提携サービスの仕入原価、設備増強による減価償却費、賃上げによる人件費、韓国代理店の会社再生法適用に伴う貸倒引当金が増加し、為替差損9,368千円も経常利益を押し下げた。今後はバイオものづくり支援サービスの売上拡大と、限られたリソースの集中投入を目指す。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.